RxSight, Inc. engages in the research, development, manufacture, and sale of light adjustable lenses and related capital equipment. The company is headquartered in Aliso Viejo, California and currently employs 461 full-time employees. The company went IPO on 2021-07-30. The firm's proprietary RxSight Light Adjustable Lens system (RxSight system) is commercially available premium cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system consists of its RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. In contrast, with the RxSight system, the surgeon implants the LAL during a standard cataract procedure, determines refractive error with patient input several weeks following surgery and then uses the LDD to modify the LAL with the precise visual correction needed to achieve the patient's desired vision outcomes.
Dr. Ron Kurtz est le President de Rxsight Inc, il a rejoint l'entreprise depuis 2016.
Quelle est la performance du prix de l'action RXST ?
Le prix actuel de RXST est de $6.35, il a diminué de 0.62% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Rxsight Inc ?
Rxsight Inc appartient à l'industrie Health Care et le secteur est Health Care
Quel est la capitalisation boursière de Rxsight Inc ?
La capitalisation boursière actuelle de Rxsight Inc est de $262.0M
Est-ce que Rxsight Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 11 analystes ont établi des notations d'analystes pour Rxsight Inc, y compris 0 achat fort, 1 achat, 10 maintien, 3 vente et 0 vente forte